Finepoint Capital LP Acquires 139,400 Shares of Arvinas, Inc. (NASDAQ:ARVN)

Finepoint Capital LP raised its stake in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 24.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 713,778 shares of the company's stock after purchasing an additional 139,400 shares during the period. Arvinas accounts for 0.8% of Finepoint Capital LP's portfolio, making the stock its 13th largest holding. Finepoint Capital LP owned 1.04% of Arvinas worth $13,683,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new position in Arvinas in the 4th quarter valued at $23,845,000. JPMorgan Chase & Co. boosted its holdings in Arvinas by 18.7% during the third quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock valued at $57,371,000 after acquiring an additional 367,343 shares during the period. FMR LLC grew its position in shares of Arvinas by 7.6% in the third quarter. FMR LLC now owns 2,883,604 shares of the company's stock valued at $71,023,000 after purchasing an additional 204,317 shares during the last quarter. BIT Capital GmbH increased its stake in shares of Arvinas by 291.7% in the fourth quarter. BIT Capital GmbH now owns 263,527 shares of the company's stock worth $5,052,000 after purchasing an additional 196,246 shares during the period. Finally, Barclays PLC lifted its position in shares of Arvinas by 198.9% during the 3rd quarter. Barclays PLC now owns 121,699 shares of the company's stock worth $2,998,000 after purchasing an additional 80,984 shares during the last quarter. Institutional investors own 95.19% of the company's stock.

Remove Ads

Arvinas Trading Up 3.9 %

Shares of Arvinas stock traded up $0.26 during mid-day trading on Friday, reaching $6.88. 1,361,876 shares of the stock were exchanged, compared to its average volume of 1,957,977. Arvinas, Inc. has a fifty-two week low of $5.93 and a fifty-two week high of $38.56. The company has a market cap of $472.81 million, a price-to-earnings ratio of -2.48 and a beta of 2.30. The firm has a 50-day simple moving average of $12.80 and a 200 day simple moving average of $19.30.

Arvinas (NASDAQ:ARVN - Get Free Report) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the company earned ($2.53) earnings per share. On average, research analysts predict that Arvinas, Inc. will post -3.81 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Ian Taylor sold 9,020 shares of the stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.71, for a total transaction of $150,724.20. Following the sale, the insider now directly owns 159,121 shares of the company's stock, valued at $2,658,911.91. This represents a 5.36 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 50,230 shares of company stock valued at $769,402. 5.23% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research analysts have commented on the company. BMO Capital Markets set a $20.00 price target on Arvinas and gave the stock an "outperform" rating in a research report on Wednesday, March 12th. Oppenheimer lowered shares of Arvinas from an "outperform" rating to a "market perform" rating in a research report on Tuesday, March 11th. Barclays reduced their price target on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a report on Monday, February 3rd. Stifel Nicolaus dropped their price objective on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Finally, Citigroup reduced their target price on shares of Arvinas from $28.00 to $19.00 and set a "neutral" rating for the company in a research note on Friday, March 7th. Five analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, Arvinas currently has a consensus rating of "Moderate Buy" and a consensus price target of $34.53.

Arvinas Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.